Table 3.
Use of Rituximab and infectious events
| References | Study | Monotherapy/combination | Patients (n°) | Phase of disease | Infections | Febrile neutropenia/FUO | Pneumonia | Sepsis | Bacterial infection | Fungine | Viral |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intermesoli et al. [24] | Phase 2 | Combined with PCT | 105, adults | Onset | 51 (49%) | 14 (13%) | 27 (26%) | ||||
| Ribera et al. [25] | Phase 2 | Combined with PCT | 118, adults | Onset | 30% | ||||||
| Hoelzer et al. [26] | Phase 4 | Combined with PCT | 265, adults | Onset | 22% | ||||||
| Maury et al. [27] | Phase 3 | Combined with PCT | 105, adults | Onset | 71 (68%) | 45 (43%) |
Candidemia 1 (1%) Aspergillosis 1 |